Breaking News Instant updates and real-time market news.

CLVS

Clovis

$59.97

0.27 (0.45%)

, RICE

Rice Energy

09:15
06/19/17
06/19
09:15
06/19/17
09:15

On The Fly: Pre-market Movers

HIGHER: Clovis (CLVS), up 52.6% after announcing the ARIEL3 study achieved the primary endpoint... Rice Energy (RICE), up 28.8% after EQT Corporation (EQT) and Rice announced they have entered into an agreement where EQT will acquire Rice for approximately $6.7B... Rigel (RIGL), up 6.8% after announcing FDA acceptance of the New Drug Application for the use of Tavalisse in patients with chronic or persistent immune thrombocytopenia... Valeant (VRX), up 3.1% after announcing that John Paulson was elected to its board. LOWER: EQT Corporation is down 5.6% following the Rice Energy acquisition announcement... Tesaro (TSRO), down 10% following Clovis's ARIEL3 study results... TripAdvisor (TRIP), down 2.1% after being downgraded to Underperform from Neutral at Credit Suisse.

CLVS

Clovis

$59.97

0.27 (0.45%)

RICE

Rice Energy

EQT

EQT Corporation

RIGL

Rigel Pharmaceuticals

$2.50

-0.12 (-4.58%)

VRX

Valeant

TSRO

Tesaro

$144.31

0.08 (0.06%)

TRIP

TripAdvisor

  • 19

    Jun

  • 30

    Jun

  • 24

    Aug

CLVS Clovis
$59.97

0.27 (0.45%)

06/16/17
FBCO
06/16/17
NO CHANGE
Target $88
FBCO
Outperform
Clovis price target raised to $88 from $74 at Credit Suisse
Credit Suisse analyst Alethia Young assumed coverage of Clovis Oncology (CLVS) and raised the firm's price target on the stock to $88 from $74, noting that her 2023 U.S. estimate for rucaparib is $1.3B versus prior coverage's forecast of $700M. Young, who thinks that the PARPi market is big enough that both Clovis and Tesaro (TSRO) can have blockbuster products, believes both companies are likely attractive targets for large global pharma companies, she tells investors. The analyst keeps an Outperform rating on Clovis shares.
06/19/17
LEER
06/19/17
NO CHANGE
LEER
Outperform
Clovis should now be 'prime takeout candidate,' says Leerink
Leerink analyst Michael Schmidt views this morning's data from Clovis Oncology (CLVS) as the "best-case outcome." The data indicate that efficacy of the three leading PARP inhibitors look very comparable, Schmidt tells investors in a research note titled "Bull Case Plays Out as ARIEL3 Hits All Endpoints." Tesaro (TSRO) and AstraZeneca (AZN) own the other leading PARP inhibitors. The analyst expects shares of Clovis to "trade up significantly" on today's news. Clovis shares in premarket trading are up 40%, or $24.03, to $84.00. "With best-case data in hand," Clovis should be a "prime takeout candidate," Schmidt tells investors. He reiterates an Outperform rating on the shares.
06/19/17
LEER
06/19/17
NO CHANGE
LEER
Market Perform
Clovis reported similar efficacy to Tesaro's Zejula, says Leerink
Leerink analyst Seamus Fernandez says the top-line efficacy data announced this morning for Clovis Oncology's (CLVS) Phase 3 Ariel3 trial of its PARP inhibitor Rubraca "were broadly similar" to that seen in Tesaro's (TSRO) Nova trial of Zejula across all patient population in second-line or greater ovarian cancer maintenance. This adds "considerable weight" to the argument that all three of these PARP inhibitors have similar activity, Fernandez tells investors in a research note. The analyst keeps a Market Perform rating on Tesaro shares.
06/19/17
CHDN
06/19/17
UPGRADE
CHDN
Neutral
Clovis upgraded to Neutral from Sell at Chardan
RICE Rice Energy

03/23/17
STFL
03/23/17
INITIATION
STFL
Buy
Rice Energy coverage resumed with a Buy at Stifel
Stifel analyst Karl J. Chalabala resumed coverage of Rice with a $32 price target and a Buy rating.
03/31/17
GHSC
03/31/17
DOWNGRADE
Target $26
GHSC
Neutral
Rice Energy downgraded to Neutral from Buy at Seaport Global
Seaport Global analysts led by Mike Kelly downgraded Rice Energy to Neutral from Buy and and lowered its price target to $26 from $28. Kelly said Rice has limited upside relative to his $2.50/Mcf long-term gas estimate and valuation is inline with peers.
02/06/17
GHSC
02/06/17
UPGRADE
GHSC
Buy
Rice Energy upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Mike Kelly upgraded Rice Energy to Buy with a $28 price target citing compelling NAV upside and continued operational improvements.
01/30/17
RHCO
01/30/17
DOWNGRADE
RHCO
Hold
Rice Energy downgraded to Hold from Buy at SunTrust
EQT EQT Corporation

01/11/17
BMOC
01/11/17
DOWNGRADE
BMOC
Market Perform
EQT Corporation downgraded on production outlook, valuation at BMO Capital
As noted earlier, BMO Capital downgraded EQT to Market Perform from Outperform. Analyst Phillip Jungwirth expects the company's 2017-18 debt-adjusted production growth to come in below that of its peers. He adds that the shares "trade at a premium to Marcellus/Utica peers on 2017-18 EV/EBITDAX." Target to $73 from $75.
05/02/17
STFL
05/02/17
NO CHANGE
STFL
EQT Corporation weakness overdone, says Stifel
Stifel analyst Karl Chalabala says that the decline in EQT's stock following its Q2 results are overdone. Despite the company's lower than expected quarterly production guidance, the analyst raised his estimates, citing "higher well productivity from increased type curves and forward gas strips continuing to grind higher." He raised his price target on the stock to $81 from $63 and keeps a Buy rating on the shares.
03/23/17
STFL
03/23/17
INITIATION
STFL
Buy
EQT Corporation coverage resumed with a Buy at Stifel
Stifel analyst Karl J. Chalabala resumed coverage of EQT with a $63 price target and a Buy rating. The analyst says that the company has the highest leverage to coming natural gas price increases.
03/13/17
TUDR
03/13/17
UPGRADE
TUDR
Buy
EQT Corporation upgraded to Buy from Hold at Tudor Pickering
Tudor Pickering analyst Jeoffrey Lambujon upgraded EQT Corporation to Buy.
RIGL Rigel Pharmaceuticals
$2.50

-0.12 (-4.58%)

09/16/16
JEFF
09/16/16
NO CHANGE
Target $9
JEFF
Buy
Jefferies views Rigel restructuring positively, ups target to $9
Jefferies analyst Eun Yang views Rigel Pharmaceuticals' restructuring, which prioritizes fostamatinib commercialization while reducing research workforce, as a positive. The analyst notes the move will have no impact on the company's early programs. She raised her price target for Rigel shares to $9 from $8.50 and keeps a Buy rating on the name. Rigel closed yesterday up 4c to $3.45. The next major catalyst for the stock will be second Phase 3 data for fostamatinib in Immune Thrombocytopenic Purpura in October or November, Yang tells investors in a research note. She expects additional indications opportunities to drive "meaningful share price appreciation."
10/20/16
JPMS
10/20/16
NO CHANGE
JPMS
Overweight
Rigel has 20%-40% near-term downside, says JPMorgan
JPMorgan analyst Anupam Rama believes shares of Rigel Pharmaceuticals now have a regulatory uncertainty overhang after the company's second phase 3 trial of fostamatinib in immune thrombocytopenic missed statistical significance on its primary endpoint.There could ultimately be a registration path forward with combined phase 3 dataset, however, Rama tells investors in a research note. Nonetheless, the analyst sees the potential for 20%-40% share downside in the near-term. Rama has an Overweight rating on Rigel. The stock is down 34% to $2.11 in pre-market trading.
10/20/16
PIPR
10/20/16
NO CHANGE
PIPR
Overweight
Rigel Pharmaceuticals risk/reward remains favorable, says Piper Jaffray
With the stock down nearly 35% in pre-market trading, Piper Jaffray analyst Joshua Schimmer believes the risk/reward on shares of Rigel Pharmaceuticals remains favorable. The company on the conference call did an "excellent job" explaining the failed second Phase III results for fostamatinib in immune thrombocytopenic, Schimmer tells investors in a research note. He believes the drug has a "clear therapeutic benefit" and reiterates an Overweight rating on the stock with an $11 price target.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
VRX Valeant

06/09/17
WELS
06/09/17
NO CHANGE
WELS
Outperform
Wells says Valeant's focus on EBITDA ignores rising borrowing costs
After Valeant Pharmaceuticals issued a regulatory filing with financial data for its just sold iNova Pharmaceuticals unit, Wells Fargo analyst David Maris says that while the company is executing deals and reducing absolute debt, "leverage seems to be relatively unchanged." Valeant's focus on EBITDA versus earnings is to have investors "ignore the impact of increased borrowing costs and any impact from potential dilutive equity based financing," Maris tells investors in a research note. Valeant has indicated an equity raise is not off the table, the analyst adds. He has an Underperform rating on the stock with a $9 price target. Valeant in afternoon trading is down 26c to $13.00.
06/16/17
CANT
06/16/17
INITIATION
Target $18
CANT
Overweight
Valeant initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Valeant Pharmaceuticals with an Overweight rating and $18 price target. The analyst believes Valeant can reduce its debt to manageable levels over the medium term and thinks new management can post earnings upside in 2019 and beyond. The analyst also thinks the negative media attention placed on the company has reduced significantly from a year ago.
06/14/17
RODM
06/14/17
NO CHANGE
Target $6
RODM
Buy
EyeGate price target lowered to $6 from $10 at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju lowered his price target for EyeGate Pharmaceuticals (EYEG( to $6 after the company granted a subsidiary of Valeant Pharmaceuticals (VRX) exclusive commercial and manufacturing rights to the EyeGate II Delivery System and EGP-437 combination product for treatment of post-operative pain and inflammation in ocular surgery patients. The analyst views the development, along with the top-line data from the first-in-human pilot trial of ocular bandage gel in patients with large corneal epithelial defects, as positive developments and raised his valuation of the company to $112M from $80M. His lowered target reflects higher shares outstanding. Selvaraju reiterates an Outperform rating on EyeGate.
06/08/17
WELS
06/08/17
NO CHANGE
Target $9
WELS
Underperform
Valeant's iNova sale to have minimal impact on debt, says Wells Fargo
Wells Fargo analyst David Maris believes Valeant Pharmaceuticals' sale of iNova Pharmaceuticals for $930M in cash, while possibly "slightly deleveraging," will not have much of an impact on the company's total debt of $28.5B, particularly if the gross proceeds are reduced by tax or other payments. The analyst notes that press reports in September suggested iNova could fetch more than $1B. Maris keeps an Underperform rating on Valeant with a $9 price target. The shares in morning trading are up 8% to $13.18.
TSRO Tesaro
$144.31

0.08 (0.06%)

06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
TRIP TripAdvisor

05/26/17
MACQ
05/26/17
DOWNGRADE
Target $33
MACQ
Underperform
TripAdvisor downgraded to Underperform from Neutral at Macquarie
06/19/17
FBCO
06/19/17
DOWNGRADE
Target $34
FBCO
Underperform
TripAdvisor downgraded to Underperform from Neutral at Credit Suisse
Credit Suisse analyst Paul Bieber downgraded TripAdvisor (TRIP) to Underperform from Neutral citing raised expectations for TV ad spending in 2018 paired with uncertainty regarding the return on TV advertising investment given the crowded ad market for online travel. Also, the stock has a premium valuation despite inferior growth compared to Priceline (PCLN) and Expedia (EXPE), said Bieber, who lowered his price target on TripAdvisor to $34 from $40.
05/26/17
05/26/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) downgraded to Neutral on balanced risk/reward at Buckingham with the firm citing more balanced risk/reward at current levels and raised its price target to $330 from $325. 2. JinkoSolar (JKS) was downgraded to Sell from Neutral at Citi and to Underweight from Overweight at Morgan Stanley. 3. Signet Jewelers (SIG) downgraded to Neutral from Buy at CL King with the firm citing lack of catalysts. 4. TripAdvisor (TRIP) downgraded to Underperform from Neutral at Macquarie with analyst Matthew Brooks saying the "best days" may be over for TripAdvisor and believes Google (GOOGL) is at the "top of the travel funnel." 5. Shire (SHPG) downgraded to Market Perform from Outperform at Bernstein with analyst Aaron Gal saying he believes risks to longer term earnings from competition and slowing Vyvanse sales are not being factored into consensus estimates. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/26/17
05/26/17
DOWNGRADE
Target $33

Underperform
TripAdvisor downgraded to Underperform on future competition at Macquarie
As previously reported, Macquarie downgraded TripAdvisor (TRIP) to Underperform from Neutral with a $33 price target, down from $52. Coverage was transferred to analyst Matthew Brooks who said the "best days" may be over for TripAdvisor and believes Google (GOOGL) is at the "top of the travel funnel." The analyst sees the future of travel search starting with travel queries addressed to AI assistants like Siri, or home devices like Amazon Echo, and expects TripAdvisor's hotel business economics to be more challenged in a world of voice and rationalization. Brooks said TripAdvisor's 500M reviews are largely text based and doesn't believe it has enough contextual information on reviewers to make the information relevant for users looking at the same travel product in the future.

TODAY'S FREE FLY STORIES

RGA

Reinsurance Group

$126.86

-0.36 (-0.28%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Reinsurance Group management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

SRCL

Stericycle

$77.24

-1.01 (-1.29%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Stericycle management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 03

    Aug

THO

Thor Industries

$107.33

-1.47 (-1.35%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Thor Industries management to meet with Cancaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 06

    Jul

IDCC

InterDigital

$79.80

-0.65 (-0.81%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
InterDigital management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

NP

Neenah Paper

$77.80

-1.6 (-2.02%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Neenah Paper management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

AGCO

AGCO

$66.47

-0.67 (-1.00%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
AGCO management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 10

    Aug

04:55
06/28/17
06/28
04:55
06/28/17
04:55
General news
Pending Home Sales Index to be reported at 10:00 »

May Pending Home Sales…

PRTS

U.S. Auto Parts

$3.23

-0.02 (-0.62%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
U.S. Auto Parts management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
JPMorgan life sciences analyst holds an analyst/industry conference call »

Life Science Tools &…

STE

STERIS

$81.47

-1.64 (-1.97%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
STERIS management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

VTR

Ventas

$71.17

-0.76 (-1.06%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Ventas management to meet with Raymond James »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

SMTC

Semtech

$34.85

-0.6 (-1.69%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Semtech management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

IVZ

Invesco

$34.77

-0.24 (-0.69%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Invesco management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

DHXM

DHX Media

$4.30

0.15 (3.61%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
DHX Media management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

04:55
06/28/17
06/28
04:55
06/28/17
04:55
General news
International Trade in Goods Balance to be reported at 08:30 »

May International Trade…

PODD

Insulet

$49.00

-1.22 (-2.43%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Insulet participates in a conference call with Leerink »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

NFG

National Fuel

$55.85

-0.45 (-0.80%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
National Fuel management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

OXY

Occidental Petroleum

$59.63

-0.38 (-0.63%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Occidental Petroleum management to meet with Evercore ISI »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

04:55
06/28/17
06/28
04:55
06/28/17
04:55
General news
Breaking General news story  »

Week of 6/23 EIA…

NBIX

Neurocrine

$45.56

-1.75 (-3.70%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Neurocrine management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 29

    Jun

LPI

Laredo Petroleum

$10.03

0.24 (2.45%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Laredo Petroleum management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

MPWR

Monolithic Power

$96.84

-2.67 (-2.68%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Monolithic Power management to meet with Oppeneimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

TRS

TriMas

$20.60

-0.1 (-0.48%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
TriMas management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

ORCL

Oracle

$50.75

-0.11 (-0.22%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Oracle management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

UNFI

United Natural Foods

$34.95

-0.08 (-0.23%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
United Natural Foods management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 13

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.